NASDAQ:OVID Ovid Therapeutics Q2 2025 Earnings Report $2.26 -0.04 (-1.74%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$2.28 +0.02 (+0.88%) As of 06/15/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ovid Therapeutics EPS ResultsActual EPS-$0.06Consensus EPS -$0.16Beat/MissBeat by +$0.10One Year Ago EPSN/AOvid Therapeutics Revenue ResultsActual Revenue$6.27 millionExpected Revenue$0.09 millionBeat/MissBeat by +$6.18 millionYoY Revenue GrowthN/AOvid Therapeutics Announcement DetailsQuarterQ2 2025Date8/13/2025TimeBefore Market OpensConference Call DateWednesday, August 13, 2025Conference Call Time3:00AM ETUpcoming EarningsOvid Therapeutics' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly report(10-Q) Ovid Therapeutics Earnings HeadlinesOvid Therapeutics (NASDAQ:OVID) Stock Rating Lowered by Wall Street ZenJune 13 at 1:48 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)June 9, 2026 | theglobeandmail.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.June 16 at 1:00 AM | Porter & Company (Ad)Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 9, 2026 | americanbankingnews.comOvid Therapeutics to Participate in Upcoming Investor ConferencesJune 4, 2026 | globenewswire.comOvid Therapeutics Expands Board, Appoints New Scientific DirectorJune 3, 2026 | tipranks.comSee More Ovid Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ovid Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ovid Therapeutics and other key companies, straight to your email. Email Address About Ovid TherapeuticsOvid Therapeutics (NASDAQ:OVID) is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need. The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome. OV101 has demonstrated proof-of-concept activity in early clinical studies, and ongoing trials aim to further characterize its safety and efficacy profiles. In parallel, Ovid is advancing OV935, a small-molecule inhibitor targeting specific kinase pathways implicated in CDKL5 deficiency disorder, a severe form of early-onset epilepsy. To support its global development strategy, Ovid has established strategic collaborations with industry partners. A notable agreement grants regional rights for OV935 to a leading pharmaceutical company for select Asian markets. The company maintains additional research partnerships to broaden its preclinical pipeline and leverage external expertise in rare disease biology and regulatory science. Ovid Therapeutics completed its initial public offering on the Nasdaq market in 2018 and continues to engage with regulatory authorities to advance its clinical programs toward potential approval. The organization is led by a management team with deep experience in neuroscience drug discovery and development, supported by a board of directors comprised of seasoned professionals in biopharma innovation and commercialization.View Ovid Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big QuestionAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationForget AI for a Moment, This Homebuilder Is Stealing the Show Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
